title: [Low doses of rtPA administered as a bolus in treatment of clinically acute massive pulmonary embolism].
abstract: 12 patients (7 male and 5 female) with confirmed pulmonary embolism (PE) with: angiography-5 cases, conventional contrast-enhanced CT-2 cases, echocardiography-2 cases, autopsy-3 cases were diagnosed as clinically acute PE. Criteria of clinically acute PE were: cardiac arrest-1 case-2 cases, shock-1 case, acute cor pulmonale-9 cases and acute cor pulmonale with shock. All patients were treated with heparin, administered with therapeutic prolongation of aPTT. Clinically acute PE (if possible confirmed with angiography, TC and/or echocardiography) was treated with rtPA administered in 10 minutes lasting bolus in doses 0.6-0.8 mg per kg of body weight (50 mg of rtPA during 10 minutes administered into peripheral veins). In 9 patients with pulmonary hypertension, significant decrease of tricuspidal gradient (measured echocardiographically during several hours after administration of rtPA) was documented. Improvement in PaO2, SaO2 and decrease of heart rate and respiratory rate were also achieved. No serious bleeding complications were observed after mentioned treatment. Control investigations (conventional contrast-enhanced CT and spiral CT) performed several days after rtPA administration revealed thrombus in pulmonary artery. We conclude: I rtPA administered in bolus simultaneously with heparin significantly decreased pulmonaryhypertension; rtPA administered simultaneously with heparin is safe method of treatment of PE; hemodynamic improvement after administration of rtPA is not univocal with full fibrynolitic effect.
authors.affiliation: Kliniki Chorób Wewnetrznych, Instytutu Gruźlicy, Warszawie.
authors.forename: W
authors.initials: W
authors.lastname: Tomkowski
authors.forename: B
authors.initials: B
authors.lastname: Borowiec
authors.forename: B
authors.initials: B
authors.lastname: Hajduk
authors.forename: J
authors.initials: J
authors.lastname: Kober
authors.forename: J
authors.initials: J
authors.lastname: Burakowski
authors.forename: K
authors.initials: K
authors.lastname: Oniszh
authors.forename: L
authors.initials: L
authors.lastname: Pawlicka
authors.forename: S
authors.initials: S
authors.lastname: Filipecki
mesh_terms: D000328:Adult; D000368:Aged; D004452:Echocardiography; D005260:Female; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000175:diagnosis / Q000188:drug therapy*; D011994:Recombinant Proteins; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D014057:Tomography, X-Ray Computed
chemical_list: D011994:Recombinant Proteins; D006493:Heparin; D010959:Tissue Plasminogen Activator